Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nom,
Are you man or women?
Nomlungu, get over it ffs.
Val is progressing and the mkt cap growth will come through shortly.
Ray - the definition of non-progression is also relevant
To meet PCWG2 criteria for non-progression (stable disease), patients must observe:
• PSA increase no greater than 25%
• Tumour size increase no greater than 20%
• No more than 1 additional metastatic lesion
The full trial results are here:
https://www.valirx.com/our-pipeline/val201
To clarify, the definition of responder given as follows:
"If no progressive disease was declared at any time that the patient was on the trial, the patient is declared a responder."
* that should read ‘less risk-averse party’
Interesting seeing whose posting today. The concern over a prospectus outlining completed funding seems to have some shorters rattled.
Little point questioning the val201 clinical data. Theoremrx think it’s worth paying millions for. Yes, the sample was too small for big pharma interest, but the results were statistically significant to warrant it being licensed from a this risk-averse party. Like it or not, TheoremRx are experts and have had a lot of time for DD. They wish to include it in their suite of oncology drugs, they’re not doing it out of charity.
It's interesting, I can't get an answer to this simple question. Instead I get pointed to smart investors or companies that intend to licence is.
I suspect I would have gotten a similar response to my question from Theranos.
Share 4, in answer:
Enough patients to license it to THX for $61mn with royalties, inflection point bonuses, monthly service agreement, $2.2mn upfront and $37mn per other indications added.
LOL
Share4 don’t you think he has better things to do on Saturday night, the rugby starts soon! Go and do your own research if you’re so interested.
PM2022, phase 1 trials typically involve 20-80 people
Can you tell me how many people have completed a trial for 201?
Porky, I have never once said this would be a phase 3 trials but phase 2b. If it was it would likely be worth over 500 million but phase 2b does have significant value so around 100/200 million valuation for the drug. I agree more data is needed but it is all about the agreements (initial payments, milestones and royalty payments) and funding for trials. More than 95% of drugs don't get funding.
The main purpose of phase 2A trials are safety and efficiency.
As far as I remember and I looked two years ago the safety record was outstanding I think the worst side effect was slightly raised blood for one patient. Efficiency 54.5% but at lower dosage therefore a huge advantage when that is increased. Note this was also for patients at late stage prostate cancer where other treatments had failed. Therefore valuable. The fact Professor Adam purchased more on the back of those results and experts have taken the drug supports what I say over all the unqualified people trying to argue otherwise.
You will not get a large pharma take this without larger data but typical deals will be worth a few hundred million or more with huge upfront payments we got less but relative to our market cap it stil multi bags by many times just on 201 alone. I think the americans will love 201 and will buy into Valirx and we will hit new highs in the coming months.
201 is priced at zero so whether you think it is worth 20,30,50 million to Val it does not cost zero to take it this far with very promising results and the deal is also not worth zero with initial and significant milestone and royalty payments attached.
Your argument is only highlighting how valuable this is relative to our current market cap of 10 million which does not even put a value on most of our other assets. Remember everything is all relative.
I think we will re-rate to a 30/40 million market cap before Christmas provided the merger goes ahead.
Anyway give it a rest now.
@Thewallcrawler
If you want to comment on others posts it's best you have a posting history of your own. No doubt as a "new member" you've changed handle to cover up your losses. You'll notice I have nothing to hide.
How many patients completed the 201 trial in 2021 PM?
Just a number will do.
@PM2022
1. You didn’t answer how many were in the trial? Now I could be wrong so please correct me but I think the answer you are searching for is 5. Of those five the safety profile was good but there was no material advantage. No peer review either other than what Adam put together. Now to be fair, it’s far too small a data set. It needs a detailed phase 2 with with 100-300 enrolled over two years to gain any meaningful data and if it’s worthy of further progression or not but that requires someone to put up serious capital to fund it. Issue is it’s yikes old now, more advanced bios are being funded. But moreover, no commercial player could be found for years to back it hence, why ultimately it was given away to this tin pot start up in 2021.
2. For what it’s worth I live in Cheshire, no where near VALs offices in Nuneaton or near Suzy even if she did reside in Nuneaton which I very much doubt. Let’s face it on £180k salary a year plus benefits, it wouldn’t surprise me if she is living in a mansion somewhere in 20 acres of farm land and most likely working from home all at Shareholders expenses.
This peeping tom BS that I live next door and watching her in her garden over a clothes line or whatever, whilst comical is rather silly and all very childish frankly but hey if it makes you smile at least it’s brightened your day.
PM2022 are you paid by VAL? When I'm invested in a stock, I either ask questions, respond to questions, or react to news. What on earth inspires you to come on this forum for several years and make repeated posts daily? The only possible reason could be to tout the stock to others, which you wouldn't need to do if there was any substance to it.
TWC - You need to read what was actually posted and understand it before you reply. Your comment 'I presume you can't name the posters you accuse of having criminal pasts then?' shows you have not read or understood what I put.
Share4,
Are you an expert like Adam working in the industry in a senior position?
Are you paying for the trials?
Are you paying VAL?
NO. I'll shut up then. I have answered your question.
Most of your posts Mr.Share4 are on VAL and PYC, if I recall you are not invested in either.
I presume you are either short on these and it's going badly, or you share Porky's rather weird fixation. Or you are Porky.
Strange times.
"How many patients completed the 201 trial in 2021 PM?"
It's not a point it's a question which has a simple answer. The fact you want to provide a narrative instead of an answer speaks volumes.
Nah I'm not considering investing. I'm here because the rampers crossed the line and started getting porky's posts removed. It tells it's own story about what's going on here.
Probably between him and his broker 😂
I presume you can't name the posters you accuse of having criminal pasts then?
Are you really sure the consolidation happened after the exit of the "gruesome twosome"?
My investments and all decisions around them are between me and my stockbroker, for obvious reasons.
So are you now considering investing?
The last time I openly considered investing here it was at 1.3p from memory, and I was advised to get in because 'after all, 201 is nailed on, funding is secure with the gruesome twosome gone, and it can't go much lower.' I didn't invest and shortly thereafter there was a 125/1 consolidation.